Yes, the circumstances may have changed somewhat with the recent failure of competitors. After chatting with an expert in the field it seems there is a growing belief that OPT302 is the most likely successful candidate to improve outcomes in combination with VEGFA inhibitors.
My view is that the recent sell down has created an opportunity for investors. Novartis was willing to pay USD1 billion for a combination therapy. Maybe the stakes are even higher now, and maybe licensing combination therapies with multiple companies products would provide an even better return.
Ann: Trading Halt, page-13
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
83.5¢ |
Change
-0.005(0.60%) |
Mkt cap ! $1.027B | |||
| Open | High | Low | Value | Volume |
| 85.5¢ | 85.5¢ | 82.0¢ | $11.20M | 13.42M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 13018 | 83.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 84.0¢ | 3897 | 1 |
View Market Depth
| Last trade - 16.10pm 31/10/2024 (20 minute delay) ? |
| OPT (ASX) Chart |